Eli Lilly
Eli Lilly and Company, established in the United States in 1876, boasts a global workforce of over 39,000 employees. Specializing in global health initiatives and diabetes care, the company offers a diverse range of human health products. With a presence in more than 120 countries, Eli Lilly has established itself as a prominent player in the pharmaceutical industry, ranking among the top companies in prescription revenue and research and development (R&D) expenditure in 2021.
Recognized for their contributions to biotechnology, Eli Lilly and Company is renowned for pioneering innovative therapies and treatments for various diseases, including cancer, diabetes, and autoimmune disorders.
Investing significantly in R&D to expand its biotech product portfolio, Eli Lilly actively develops and markets a range of biotech medicines, such as monoclonal antibodies, gene therapies, and other groundbreaking treatments. Additionally, the company collaborates with other biotech and pharmaceutical firms to drive the development of new medicines and technologies.
In 2022, Trulicity emerged as Eli Lilly's top revenue-generating product, earning approximately 7.4 billion USD. Following closely, Verzenio achieved significant profitability, generating around 2.4 billion USD in sales.
Eli Lilly stands as a prominent manufacturer of leading prescription medicines and therapies for diabetes. In 2017, the company ranked as the second-largest seller of anti-diabetic drugs based on revenue. Trulicity, one of Eli Lilly's key medications for type II diabetes treatment, is projected to become the leading anti-diabetic pharmaceutical by 2024.
Founded: 1876
Headquarters: Indianapolis, Indiana, U.S.
Website: https://www.lilly.com/
